Archive · 2 Aug 2025
India's New Drug Approval Rules Aim for Transparency and Efficiency
India is changing how it checks new medicines and medical tools.
They're making rules for the experts who decide if a drug is safe and works.
These rules will help the experts make their decisions in a fair way, like using a specific checklist, so things are approved faster and easier to understand.
This change follows suggestions from a world health group, so that the drug approvals in India are as safe and good as other places.
It is hoped these steps will help companies and improve the health system.
India unveils formal rules for expert panels to vet new drugs and medical devices.
The guidelines aim to make regulatory decisions faster, more predictable, and transparent.
The new rules standardize how Subject Expert Committees (SECs) are formed and how they must evaluate applications.
The overhaul follows recommendations from the World Health Organization (WHO) to align India's system with global standards.
The changes address concerns about inconsistent and opaque drug approval processes that had delayed launches.
- Who
- The Central Drugs Standard Control Organization (CDSCO)
- What
- India issued its first formal playbook for how expert panels should vet new drugs, biologics, and medical devices.
- When
- The CDSCO finalized the guidelines about two weeks ago.
- Where
- India
- Why
- To fix concerns about inconsistent and opaque approvals that have delayed drug launches and eroded industry trust in the regulatory system.
Government
Pharmaceutical Industry
Streamlined Approval Process
Government
Faster approvals and greater transparency.
Pharmaceutical Industry
Industry concerns over the unpredictability of SEC verdicts will be reduced.
- Organization
- Central Drugs Standard Control Organization (CDSCO)
- Industry Ranking
- 3rd globally by volume, 14th by value
- Products
- 60,000+ across 60 therapeutic areas
- SEC Membership
- 8 experts; 1 pharmacologist, 7 specialists
- SEC Term
- 3 years